Title: Menopause does not modulate the benefit of CDK4/6 inhibitors in adjuvant setting: phase III meta-analysis
Type: B (clinical / real-world)
Tags: CDK4/6, HR+ breast cancer, adjuvant, menopause, ribociclib, abemaciclib
PMID: 42593586
DOI: 10.1007/s10549-026-08056-7
Journal: Breast Cancer Research and Treatment (2026)
Category: Oncology

---

⚖️ Transparency notice: this article was written with AI assistance and reviewed by the author, a medical oncologist.

The central finding

Meta-analysis of 4 phase III trials (17,748 patients, 45% pre/perimenopausal, 55% postmenopausal) in early HR+/HER2- breast cancer with adjuvant CDK4/6i. The iDFS benefit does not differ by menopausal status: pooled HR 0.80 (95% CI 0.67-0.97, I²=64%) in pre/peri vs 0.79 (95% CI 0.72-0.86, I²=0%) in postmenopausal. No significant subgroup difference for iDFS or OS [PMID 42593586].

The numbers

Subgroup	iDFS HR (95% CI)	I²	OS HR (95% CI)	I²
Pre/peri	0.80 (0.67-0.97)	64%	1.02 (0.67-1.54)	80%
Post	0.79 (0.72-0.86)	0%	0.89 (0.78-1.03)	0%

Pre/peri had 3.0% fewer absolute iDFS events at 5-6 years vs postmenopausal. Sensitivity analysis limited to ribociclib/abemaciclib = consistent [PMID 42593586].

Critical reading

1. High heterogeneity in pre/peri (I²=64% iDFS, 80% OS). The authors attribute it to differences in endocrine backbone, tumor characteristics, and risk — not to menopausal status per se. This is key: the effect of CDK4/6i in premenopausal women depends on whether they receive ovarian suppression (OFS), which this MA does not separate well [PMID 42593586].
2. Does not distinguish OFS vs tamoxifen alone. Same limitation as the AMH analysis of RxPONDER (Kalinsky 2026): the real question —does chemo/CDK4/6 benefit from cytotoxic effect or from ovarian suppression?— remains open.
3. OS not mature / not significant. HR OS ~1.0 in pre/peri suggests that the iDFS benefit has not yet translated to overall survival.
4. MA of aggregate data (trial-level), not IPD. Cannot adjust for individual covariates.

💡 Implications for consultation

Menopausal status alone should NOT be used to decide on adjuvant CDK4/6i: the benefit is similar. What DOES matter (and this MA does not resolve) is the endocrine backbone — if a young premenopausal patient receives OFS + CDK4/6i, the benefit may differ from the tamoxifen-only arm. Connects with the AMH/RxPONDER post: ovarian reserve, not stated age, may be the real biomarker.

Reference: Bender U, et al. Breast Cancer Res Treat. 2026;218(3):43. doi:10.1007/s10549-026-08056-7. PMID: 42593586.

— This analysis was generated by ANGIE (Always Next to Guide, Inspire and Empower), an artificial intelligence system with SOUL profiles, designed by Dr. Javier Pumares Pérez.

Connect on LinkedIn · ppj.es